In a changing global development economic and human rights landscape Presented at the International AIDS amp Economics Network Preconference Melbourne July 2014 Emily Donaldson AVAC Presenting on behalf of the ID: 1043642
Download Presentation The PPT/PDF document "HIV Prevention Research & Developmen..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. HIV PreventionResearch & Development Investment in 2013 In a changing global development, economic, and human rights landscapePresented at the International AIDS & Economics Network Pre-conference, Melbourne, July 2014Emily Donaldson, AVACPresenting on behalf of the HIV Vaccines & Microbicides Resource Tracking Working Group
2. MethodologyComprehensive and consistent investment data collection and disaggregation methodology since 2004Data collection January – June 2014HIV Vaccines & Microbicides Resource Tracking Working GroupData Sources:Public funders (447 grants)Philanthropic (141 grants)Industry (7 grants)R&D Categories:Preventive HIV vaccines (307 grants)Microbicides (84 grants)Pre-exposure prophylaxis (54 grants)Treatment as prevention (80 grants)Male circumcision (20 grants)Female condom (4 grants)Prevention of vertical transmission (24 grants)HSV-2 vaccines (22 grants) HIV cure (150 grants)Therapeutic HIV vaccines (45 grants)
3. Global HIV Prevention R&D Investment, 2009 – 2013(US$ millions)US$1.26BUS$1.31BUS$1.28BUS$1.27BUS$1.22BHIV Vaccines & Microbicides Resource Tracking Working Group
4. Global HIV Prevention R&D Investment 2013 by Funder Type(US$ millions)HIV Vaccines & Microbicides Resource Tracking Working Group
5. Global HIV Prevention R&D Investment 2012 & 2013(US$ millions)Funding SourceAmount 2013Amount 2012% Change from 2012US Public-Sector887925-4%European Public-Sector7786-10%Other Governments6569-6%Philanthropic193203-5%Industry3734+9%All HIV Prevention R&D1.261.31-4%HIV Vaccines & Microbicides Resource Tracking Working Group
6. 2013 Investment and Year-Over-Year ChangeHIV Vaccines & Microbicides Resource Tracking Working Group
7. $154M2013 International Development Funding HIV Vaccines & Microbicides Resource Tracking Working Group
8. Global HIV Prevention R&D Investment 2013 by Prevention Option(US$ millions)HIV Vaccines & Microbicides Resource Tracking Working Group
9. Global HIV Prevention R&D Investment 2012 & 2013(US$ millions)HIV Prevention OptionAmount 2013Amount 2012% Change from 2012Preventive HIV vaccines818 847-3%Microbicides210245-14%Pre-exposure Prophylaxis3631+16%Treatment as Prevention 11798+19%Male circumcision3241.6-23%Female condoms2.22+10%Prevention of vertical transmission4443.8+0.5%All HIV Prevention R&D1.261.31-4%HIV Vaccines & Microbicides Resource Tracking Working Group
10. HIV Prevention Trial Participants by Region 2013
11. Advocacy, policy and funding trendsThe US public sector funds the majority of HIV prevention R&D. Philanthropic organizations increasingly fund vital parts of HIV prevention research.Industry funding stayed almost flat and shifted to later development stages.International development priorities are evolving.The enabling environment has a profound effect on where trials take place and whether they are able to happen.HIV Vaccines & Microbicides Resource Tracking Working Group
12. AcknowledgementsSignificant contributions from the Working Group organizations, AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Working Group members Kevin Fisher (AVAC), Reuben Granich (UNAIDS), Thomas Harmon (IAVI), Polly Harrison (AVAC) and Mitchell Warren (AVAC).
13. For the full report, including graphics and past reports, visit www.hivresourcetracking.org